FDA stamps approval on new allergy med; Duke-led research uncovers clinical trial shortcomings;

 @FierceBiotech: Genomics tops chart of social media buzz in biotech IT. Story | Follow @FierceBiotech

 @JohnCFierce: Any promising biotech with a late-stage asset looking to do a deal in the $1B-$5B arena is positioned just right. More | Follow @JohnCFierce

 @RyanMFierce: Lots of activity in developing weight drugs that target brown fat. Roche, Eli Lilly, and two biotech startups are in the hunt. Article | Follow @RyanMFierce

 @MarkHFierce: Pancreatic cancer cases often have a "brake gene" turned off, U.K. scientists found, that lets the tumors spread. Story | Follow @MarkHFierce

> University of California San Francisco Chancellor Susan Desmond-Hellmann (photo), a former head of development at Genentech, foresees a more dynamic approach to advancing products and other major shifts in healthcare. Interview

> Swedish drug company Meda has won FDA approval for its new allergy med Dymista. Release

> A Duke University-led study of more than 40,000 drug and device trials found that most of the studies lacked adequate size and quality. Article

Pharma News

 @FiercePharma: Watchdogs at IOM say FDA should be more vigilant on post-marketing safety. Plus, its safety communications are muddled. Article | Follow @FiercePharma

> Hedge fund claims Savient's bankrupt after failed Krystexxa launch. Item

> Novartis digs into safety data in Avastin-vs.-Lucentis study. Story

> IOM takes FDA to task on post-marketing safety. More

> Men flock to testosterone meds from Abbott, Lilly. News

Medical Devices News

@FierceMedDev: Study: Doctors use device and drug trials of spotty quality. Story | Follow @FierceMedDev

> Thoratec earnings soar, fueled by HeartMate II LVAD sales surge. News

> Covidien closes $108M bid for Newport Medical. More

> Dentsply sees Q1 profit drop, sales jump. Article

> Germany scrutinizes Siemens over alleged Russian payments. Item

Biomarkers News

> Scans for autism gene groups could open door to genetic biomarkers. More

> Pancreatic cancer protein biomarker could predict outcomes. Item

> Epigenetics signal possible breast cancer blood test. Story

> Weight loss cuts inflammation, cancer markers. Article

Drug Delivery News

 @DamianFierce: Ever wonder exactly how wireless drug delivery works? Well, wonder no longer. News | Follow @DamianFierce

> Swedish discovery could be key to better transdermal delivery. Article

> Researchers develop 'smart' nanostructures for drug delivery. Story

> Genericsmaker banking on novel delivery to raise funds. Item

> Aptar launches new inhaler with eye on emerging markets. News

And Finally… Merck ($MRK) has tapped Trevena, which specializes in research of G-protein coupled receptors, to collaborate on a drug-discovery program. Details

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.